Abstract
This secondary analysis of a randomized clinical trial examines the risk of kidney or hepatic toxic effects among patients with impaired kidney function at baseline treated with remdesivir.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenosine Monophosphate / analogs & derivatives
-
Adenosine Monophosphate / therapeutic use
-
Alanine* / analogs & derivatives
-
Alanine* / therapeutic use
-
Humans
-
Kidney Diseases*
-
Kidney*
Substances
-
remdesivir
-
Adenosine Monophosphate
-
Alanine